Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intracoronary compared to intravenous bolus abciximab during primary percutaneous coronary intervention in ST-segment Elevation Myocardial Infarction (STEMI) patients reduces 30-day mortality and target vessel revascularization: a randomized trial.
Iversen A, Abildgaard U, Galloe A, Hansen PR, Galatius S, Madsen JK, Engstroem T, Pedersen S, Jensen KS, Jensen JS. Iversen A, et al. J Interv Cardiol. 2011 Apr;24(2):105-11. doi: 10.1111/j.1540-8183.2010.00616.x. Epub 2010 Dec 22. J Interv Cardiol. 2011. PMID: 21175845 Free article. Clinical Trial.
Intracoronary compared to intravenous abciximab in patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention reduces mortality, target vessel revascularization and reinfarction after 1 year.
Iversen AZ, Galatius S, Abildgaard U, Galloe A, Hansen PR, Pedersen S, Engstroem T, Jensen JS. Iversen AZ, et al. Cardiology. 2011;120(1):43-9. doi: 10.1159/000333117. Epub 2011 Nov 23. Cardiology. 2011. PMID: 22122887 Clinical Trial.
Field triage reduces treatment delay and improves long-term clinical outcome in patients with acute ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
Pedersen SH, Galatius S, Hansen PR, Mogelvang R, Abildstrom SZ, Sørensen R, Davidsen U, Galloe A, Abildgaard U, Iversen A, Bech J, Madsen JK, Jensen JS. Pedersen SH, et al. J Am Coll Cardiol. 2009 Dec 8;54(24):2296-302. doi: 10.1016/j.jacc.2009.06.056. J Am Coll Cardiol. 2009. PMID: 19958965 Free article.
10-Year Clinical Outcome After Randomization to Treatment by Sirolimus- or Paclitaxel-Eluting Coronary Stents.
Galløe AM, Kelbæk H, Thuesen L, Hansen HS, Ravkilde J, Hansen PR, Christiansen EH, Abildgaard U, Stephansen G, Lassen JF, Engstrøm T, Jensen JS, Jeppesen JL, Bligaard N; SORT OUT II Investigators. Galløe AM, et al. J Am Coll Cardiol. 2017 Feb 14;69(6):616-624. doi: 10.1016/j.jacc.2016.11.055. J Am Coll Cardiol. 2017. PMID: 28183505 Free article. Clinical Trial.
SuPAR is associated with death and adverse cardiovascular outcomes in patients with suspected coronary artery disease.
Hodges G, Lyngbæk S, Selmer C, Ahlehoff O, Theilade S, Sehestedt TB, Abildgaard U, Eugen-Olsen J, Galløe AM, Hansen PR, Jeppesen JL, Bang CN. Hodges G, et al. Among authors: galloe am. Scand Cardiovasc J. 2020 Dec;54(6):339-345. doi: 10.1080/14017431.2020.1762917. Epub 2020 May 13. Scand Cardiovasc J. 2020. PMID: 32400206 Free article.
76 results